Date Title Description PDF
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
14 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 7 March 2022 and 11 March 2022 Download
07 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 28 February 2022 and 4 March 2022 Download
28 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 23 February 2022 and 25 February 2022 Download
23 Feb 2022 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors Download
23 Feb 2022 Annual Corporate Governance Report ROVI releases the 2021 Annual Corporate Governance Report Download

Pages

Date Title Description PDF
07 Nov 2019 Information on P&L ROVI releases the first nine months 2019 results presentation Download
03 Oct 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the third quarter of 2019 Download
05 Sep 2019 Others on business performance and financial information The Company informs about the construction of a second heparin plant in Granada Download
30 Jul 2019 Information on P&L ROVI releases the first half 2019 results presentation Download
30 Jul 2019 Information on P&L ROVI releases the press release related to the first half 2019 financial results Download

Pages